Lynx1 Capital Management LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Lynx1 Capital Management LP reported 22 stock positions worth $494.0 million. Its top holding was Stoke Therapeutics (STOK) at 34.7% of the portfolio, followed by GH Research (GHRS, 26.8%) and Cullinan Therapeutics (CGEM, 18.8%). Compared with Q3 2025, it opened 13 new positions, sold out of 5, added to 5 and reduced 1. The biggest buy was Cullinan Therapeutics (CGEM, shares +55%) and the biggest sale an exit from Merus (MRUS).
- Most Recent 13F
- Q2 2026
- Location
- DORADO, PR
- CIK
- 0001910456
- Portfolio Value
- $494.0M (Q4 2025)
- SEC Filing
- 0001910456-26-000001 ↗ filed Feb 17, 2026
Holdings Value
Holdings 22 stocks · $494.0M
| STOK Stoke Therapeutics Inc. | 34.73% | 5,404,674 | $171.5M | No change |
| GHRS GH Research PLC | 26.75% | 10,406,575 | $132.2M | Add +21.0% |
| CGEM Cullinan Therapeutics Inc. | 18.78% | 8,963,500 | $92.8M | Add +55.5% |
| DNLI Denali Therapeutics Inc. | 5.81% | 1,738,750 | $28.7M | Add +564.4% |
| CCCC C4 Therapeutics Inc. | 2.74% | 7,098,133 | $13.6M | No change |
| XNCR Xencor Inc. | 2.19% | 705,558 | $10.8M | New |
| IMTX Immatics NV | 1.96% | 921,950 | $9.7M | New |
| TCRX Tscan Therapeutics Inc. | 1.62% | 8,019,148 | $8.0M | Add +2.1% |
| PASG Passage Bio Inc. | 1.49% | 623,704 | $7.4M | No change |
| KRRO Korro Bio Inc. | 1.10% | 677,915 | $5.4M | New |
| DTIL Precision Biosciences Inc. | 0.84% | 993,913 | $4.1M | Reduce -4.7% |
| NEUP Neuphoria Therapeutics Inc. | 0.69% | 875,228 | $3.4M | New |
| AGIO Agios Pharmaceuticals Inc. | 0.44% | 79,624 | $2.2M | New |
| CGON CG Oncology Inc. | 0.27% | 31,591 | $1.3M | New |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.16% | 12,043 | $800K | New |
| DSGN Design Therapeutics Inc. | 0.13% | 69,516 | $652K | Add +5.4% |
| TRDA Entrada Therapeutics Inc. | 0.11% | 51,689 | $531K | New |
| HOWL Werewolf Therapeutics Inc. | 0.08% | 655,926 | $416K | New |
| MPLT Maplight Therapeutics Inc. | 0.05% | 13,477 | $237K | New |
| GBIO Generation Bio Co. | 0.03% | 25,000 | $142K | New |
| PRQR Proqr Therapeutics NV | 0.03% | 68,486 | $138K | New |
| APLT Applied Therapeutics Inc. | 0.01% | 410,500 | $41K | New |
Portfolio Sells Q3 2025 → Q4 2025
Portfolio Buys Q3 2025 → Q4 2025
| CGEM Cullinan Therapeutics Inc. | Add +55.5% | 18.78% | +11.82 |
| GHRS GH Research PLC | Add +21.0% | 26.75% | +5.52 |
| DNLI Denali Therapeutics Inc. | Add +564.4% | 5.81% | +5.04 |
| XNCR Xencor Inc. | New | 2.19% | +2.19 |
| IMTX Immatics NV | New | 1.96% | +1.96 |
| KRRO Korro Bio Inc. | New | 1.10% | +1.10 |
| NEUP Neuphoria Therapeutics Inc. | New | 0.69% | +0.69 |
| AGIO Agios Pharmaceuticals Inc. | New | 0.44% | +0.44 |
| CGON CG Oncology Inc. | New | 0.27% | +0.27 |
| ARWR Arrowhead Pharmaceuticals Inc. | New | 0.16% | +0.16 |
| TRDA Entrada Therapeutics Inc. | New | 0.11% | +0.11 |
| HOWL Werewolf Therapeutics Inc. | New | 0.08% | +0.08 |
| MPLT Maplight Therapeutics Inc. | New | 0.05% | +0.05 |
| DSGN Design Therapeutics Inc. | Add +5.4% | 0.13% | +0.03 |
| GBIO Generation Bio Co. | New | 0.03% | +0.03 |
| PRQR Proqr Therapeutics NV | New | 0.03% | +0.03 |
| APLT Applied Therapeutics Inc. | New | 0.01% | +0.01 |
| TCRX Tscan Therapeutics Inc. | Add +2.1% | 1.62% | −1.29 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026Amended | 27 | $865.5M | GHRS, CGEM, STOK, AGIO, CCCC |
| Q1 2026 | 23 | $632.7M | STOK, GHRS, CGEM, AGIO, DNLI |
| Q4 2025 | 22 | $494.0M | STOK, GHRS, CGEM, DNLI, CCCC |
| Q3 2025 | 14 | $491.3M | MRUS, STOK, GHRS, PTGX, CGEM |
| Q2 2025 | 15 | $346.2M | MRUS, GHRS, STOK, PTGX, CGEM |
| Q1 2025 | 14 | $279.2M | GHRS, MRUS, PTGX, STOK, CGEM |
| Q4 2024 | 18 | $266.7M | MRUS, STOK, GHRS, CCCC, ALLO |
| Q3 2024 | 18 | $282.2M | MRUS, STOK, CCCC, GHRS, TCRX |
| Q2 2024Amended | 17 | $277.2M | MRUS, STOK, GHRS, CCCC, TCRX |
| Q1 2024Amended | 16 | $388.2M | ALPN, MRUS, STOK, TCRX, CABA |